Anthracycline-Induced Cardiomyopathy

References

• Jones R, Swanton C, Ewer M. Anthracycline cardiotoxicity. Expert OpinDrug Saf. 2006; 5(6): 791–809.
   PubMed Web of Science ®Google Scholar
• Kim K, Oudit GY, Backx PH. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther. 2008; 324(1): 164–169.
   Google Scholar
• Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006; 114(23): 2474–2481.
   PubMed Web of Science ®Google Scholar
• Kalay N, Basar E, Ozdogru I, et al. Protective effects of Carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006; 48(11): 2258–2262.
   PubMed Web of Science ®Google Scholar
• Boucek RJ Jr, Stelle A, Miracle A, Atkinson J. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2003; 3(4): 319–329.
   PubMedGoogle Scholar
• Simpson C, Herr H, Courville KA. Concurrent therapies that protect against doxorubicin-induced cardiomyopathy. Clin J Oncol Nurs. 2004; 8(5): 497–501.
   Google Scholar
• Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996; 125(1): 47–58.
   PubMed Web of Science ®Google Scholar
• Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin One. 2004; 22(24): 4979–4990.
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Greenland P, Grundy SM. AHA Conference Proceedings: Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. Circulation. 2000; 101(1): 111–116.
   PubMedGoogle Scholar
• Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005; 112(24): 3754–3762.
   PubMed Web of Science ®Google Scholar
• Jungsuwadee P, Cole M, Sultana R, et al. Increase in Mrpl expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice. Mol Cancer Ther. 2006; 5(11): 2851–2860.
   Google Scholar
• Hasan S, Dinh K, Lombardo F, Kark J. Doxorubicin cardiotoxicity in African-Americans. J Natl Med Assoc. 2004; 96(2): 196–199.
   Google Scholar
• Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008; 26(8): 1231–1238.
   PubMed Web of Science ®Google Scholar
• Huang RS, Duan S, Kistner EO, et al. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008; 68(9): 3161–3168.
   PubMed Web of Science ®Google Scholar
• Oliveira PJ, Gonçalves L, Monteiro P, Providencia LA, Moreno AJ. Are the antioxidant properties of Carvedilol important for protection of the cardiac mitochondria? Curr Vase Pharmacol. 2005; 3(2): 147–158.
   Google Scholar
• Topol E, Califf R, Prystowsky E, Thomas J, Thompson P. Textbook of Cardiovascular Medicine. Philadelphia, PA: Lippencott, Williams and Wilkins; 2007: 1422.
   Google Scholar
• Okumura K, Jin D, Takai S, Miyazaki M. Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol. 2002; 88(2): 183–188.
   Google Scholar
• Oliveira PJ, Bjork JA, Santos MS, et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol. 2004; 200(2): 159–168.
   PubMed Web of Science ®Google Scholar
• Floyd J, Morgan J, Perry M, et al. Cardiotoxicity of anthracycline-like chemotherapy agents, www.uptodate.com. Published May 20 2008. Assessed July 2008.
   Google Scholar
• Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007; 49(5): 330–352.
   PubMed Web of Science ®Google Scholar
• Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol. 2007; 7(2): 129–134.
   PubMed Web of Science ®Google Scholar
• Robert J. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovasc Toxicol. 2007; 7(2): 135–139.
   Google Scholar
• Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling, and failure. Cardiovasc Res. 2006; 71(2): 208–215.
   Google Scholar
• Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkiö M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol. 2003; 21(12): 2349–2356.
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Massey MR, Baysinger KB, et al. Superior detection of cardiotoxicity during chemotherapy using biomarkers. J Card Fail. 2007; 13: S151.
   Google Scholar
• Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004; 109(22): 2749–2754.
   PubMed Web of Science ®Google Scholar
• Carver J, Shapiro C, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007; 25(25): 3991–4008.
   PubMed Web of Science ®Google Scholar
• Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996; 53(6): 461–470.
   PubMed Web of Science ®Google Scholar
• Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Møller H. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer. 2007; 7: 9.
   PubMed Web of Science ®Google Scholar
• Hashimoto I, Ichida F, Miura M, et al. Automatic border detection identifies subclinical anthracycline cardiotoxicity in children with malignancy. Circulation. 1999; 99(18): 2367–2370.
   Google Scholar
• Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol. 1986; 58(7): 607–613.
   Google Scholar
• Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress echocardiography. Eur J Pediatr. 2001; 160: 607–610.
   PubMed Web of Science ®Google Scholar
• Rohde LE, Baldi A, Weber C, et al. Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity. Int J Cardiovasc Imaging. 2007; 23(2): 185–191.
   Google Scholar
• Tjeerdsma G, Meinardi MT, van Der Graaf WT, et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart. 1999; 81(4): 419–423.
   Google Scholar
• Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child. 1996; 75(5): 416–422.
   PubMed Web of Science ®Google Scholar
• Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr. 2003; 162(10): 690–696.
   Google Scholar
• Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002; 13: 699–709.
   PubMed Web of Science ®Google Scholar
• Gottdiener JS, Mathisen DJ, Borer JS, et al. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med. 1981; 94(4 part 1): 430–435.
   Google Scholar
• De Wolf D, Suys B, Verhaaren H, Matthys D, Taeymans Y. Low-dose dobutamine stress echocardiography in children and young adults. Am J Cardiol. 1998; 81(7): 895–901.
   Google Scholar
• Nousiainen T, Jantunen D, Vanninen D, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002, 86(11): 1697–1700.
   Google Scholar
• Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987; 9(1): 184–188.
   Google Scholar
• Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23(12): 2629–2636.
   PubMed Web of Science ®Google Scholar
• Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin- induced systolic dysfunction in humans. J Am Coll Cardiol. 1992; 20(1): 62–69.
   PubMedGoogle Scholar
• Kapusta L, Thijssen JM, Groot-Loonen J, Antonius T, Mulder J, Daniëls O. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol. 2000; 26(7): 1099–1108.
   Google Scholar
• Nagy AC, Tolnay E, Nagykálnai T, Forster T. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI. Neoplasma. 2006; 53(6): 511–517.
   Google Scholar
• Nagy AC, Cserép Z, Tolnay E, Nagykálnai T, Forster T. Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study. Pathol Oncol Res. 2008; 14(1): 69–77.
   Google Scholar
• Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl J Med. 1998; 339(13): 900–905.
   PubMed Web of Science ®Google Scholar
• Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol. 1992; 70(1): 73–77.
   Web of Science ®Google Scholar
• Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM. Acute arrhythmogenicity of doxorubicin administration. Cancer. 1987; 60(6): 1213–1218.
   Google Scholar
• Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973; 32: 302–314.
   PubMed Web of Science ®Google Scholar
• Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987; 82(6): 1109–1118.
   PubMed Web of Science ®Google Scholar
• Bien S, Riad A, Ritter CA, et al. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007; 67(21): 10428–10435.
   Google Scholar